Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Bolt Biotherapeutics (BOLT) EPS (Basic) (2020 - 2025)

Bolt Biotherapeutics (BOLT) has disclosed EPS (Basic) for 6 consecutive years, with -$3.91 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) rose 53.06% to -$3.91 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$12.38 through Dec 2025, up 55.24% year-over-year, with the annual reading at -$17.85 for FY2025, 46.01% up from the prior year.
  • EPS (Basic) hit -$3.91 in Q4 2025 for Bolt Biotherapeutics, down from -$3.72 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of -$0.28 in Q1 2024 to a low of -$11.12 in Q2 2024.
  • Historically, EPS (Basic) has averaged -$2.37 across 5 years, with a median of -$0.64 in 2021.
  • Biggest five-year swings in EPS (Basic): skyrocketed 95.03% in 2021 and later plummeted 2216.67% in 2024.
  • Year by year, EPS (Basic) stood at -$0.73 in 2021, then grew by 27.4% to -$0.53 in 2022, then increased by 11.32% to -$0.47 in 2023, then plummeted by 1672.34% to -$8.33 in 2024, then skyrocketed by 53.06% to -$3.91 in 2025.
  • Business Quant data shows EPS (Basic) for BOLT at -$3.91 in Q4 2025, -$3.72 in Q3 2025, and -$4.46 in Q2 2025.